UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/548,748	09/08/2005	Markus Frank	12810-00137-US	1250
	7590 04/09/200 BOVE LODGE & HUT	EXAMINER		
PO BOX 2207		IBRAHIM, MEDINA AHMED		
WILMINGTON, DE 19899			ART UNIT	PAPER NUMBER
		1638		
			MAIL DATE	DELIVERY MODE
			04/09/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/548,748	FRANK ET AL.	
Examiner	Art Unit	

	Medina A. Ibrahim	1638	
The MAILING DATE of this communication appe	ars on the cover sheet with the o	correspondence add	ress
THE REPLY FILED <u>09 March 2009</u> FAILS TO PLACE THIS AP	PLICATION IN CONDITION FOR	ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appelor Continued Examination (RCE) in compliance with 37 Coperiods:	the same day as filing a Notice of a replies: (1) an amendment, affidavi eal (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires <u>3</u> months from the mailing date	of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(1)	ater than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	g date of the final rejection	n.
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	on which the petition under 37 CFR 1.1 ension and the corresponding amount of hortened statutory period for reply origi than three months after the mailing dat	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed with AMENDMENTS 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection, be	out prior to the date of filing a brief	will not be entered be	Called
(a) They raise new issues that would require further cor			cause
(b) They raise the issue of new matter (see NOTE below			
(c) They are not deemed to place the application in bet	ter form for appeal by materially red	ducing or simplifying th	ne issues for
appeal; and/or (d) ☐ They present additional claims without canceling a c	corresponding number of finally reje	ected claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)).			
4. The amendments are not in compliance with 37 CFR 1.12	21. See attached Notice of Non-Co	mpliant Amendment (I	PTOL-324).
5. 🛮 Applicant's reply has overcome the following rejection(s):			
 Newly proposed or amended claim(s) would be all non-allowable claim(s). 	owable if submitted in a separate, t	timely filed amendmer	nt canceling the
7. X For purposes of appeal, the proposed amendment(s): a) [will not be entered, or b) will will will will will will will	I be entered and an ex	xplanation of
how the new or amended claims would be rejected is prov	ided below or appended.		
The status of the claim(s) is (or will be) as follows: Claim(s) allowed:			
Claim(s) objected to:			
Claim(s) rejected: <u>1-3,6-9,11,14-17,19,20,23 and 25-27</u> . Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	al and/or appellant fails	s to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attache	ed.
11. X The request for reconsideration has been considered but See Continuation Sheet.	t does NOT place the application in	condition for allowand	ce because:
12. ☐ Note the attached Information <i>Disclosure Statement</i>(s). (13. ☐ Other: <u>See Continuation Sheet</u>.	PTO/SB/08) Paper No(s)		
	/Medina A Ibrahim/ Primary Examiner, Art U	Init 1638	

Continuation of 11. does NOT place the application in condition for allowance because: the arguments regarding scope 103 rejection are duplicatives of what have been previously addressed.

Continuation of 13. Other: Applicant argues that the combination of Simmons and Hickelhoven does not render the claimed invention obvious because Applicant asserts that none of the references suggest generating transgenic plants with improved disease resistance using BI1 gene, wherein the expression of BI1 protein remains unchanged in the leaf or epidermis while increasing the expression in the mesophyll of the plant. These are not found persuasive because in Example 7, Simmons et al teach methods of altering BI1 expression in transgenic plants using tissue-specific promoters. In Example 11, the cited reference teaches methods of inducing resistance against ear mold disease by altering expression of the BI1 gene using promoters specific to the tissue most accounting for ear mold ingress, namely silks, husks, pericarp or cob. Example 13 of the specification shows reducing the expression level of BI1 protein in tapetum tissues using antisense BI1 constructs containing tapetum -specific promoter. The use of a tissue-specific promoter that is different from the tissue-specific promoter used by the prior art would not render the claimed invention unobvious.